ProShares Ultra Health Care (RXL) Son Haberler, Pazar Güncellemeleri ve Duygusal Durum | Edgen
Geri
Ana sayfa
Stok
RXL
ProShares Ultra Health Care (RXL)
RXL Hisse Senedi Fiyat Grafiği
RXL
ProShares Ultra Health Care
$56.59
-1.27%
$-0.72
Kapanışta: Sep 10, 16:00:00 GMT-4
$56.59
0%
$0
Sonrası Piyasa: Sep 10, 20:00:00 GMT-4
Genel bakış
Tahmin
Varlıklar
Haberler
Makale
Önemli İstatistikler
Önceki Kapanış
$57.32
Açılış fiyatı
$56.96
Günün Aralığı
$56.55 - $57.47
52 haftalık aralık
$39.32 - $64.59
İşlem hacmi
6.0K
Ort.Hacim
11.1K
Dividend yield
1.55%
Net Varlıklar
$0
NAV
--
Gider Oranı
--
Dolaşımındaki Paylar
1.5M
RXL nedir?
RXL was created on 2007-01-30 by ProShares. The fund's investment portfolio concentrates primarily on health care equity. RXL provides 2x leveraged exposure to a cap-weighted index of US health care companies.
Özellikler
AI Yardımcısı İçin Hisse ve Kripto
Fiyat Tahmini
Para Takibi
Kripto Karşılaştırması
Ana Sayfa
Markets
US Stocks
HK Stocks
Crypto
News
Analyst Moves
Market Moves
Hong Kong IPO
Earnings
AI & Technology
Macro & Policy
Kullanım Şartları
Gizlilik Politikası
Site Haritası
© 2026 Edgen, tr'ye dayalı
Merck lifts pipeline target to $70B as KEYTRUDA cliff nears
Sep 10 2026, 10:37
Amgen falls 10% as Novartis Lp(a) trial failure clouds drug class
Sep 08 2026, 17:27
Moderna-Merck vaccine clears Phase 3, stock jumps 177% on melanoma data
Sep 06 2026, 18:55
Viking Therapeutics trades below targets as VK2735 oral safety questioned
Sep 06 2026, 00:57
Gilead's third FDA approval in 4 months lifts turnaround case
Sep 05 2026, 16:28
AbbVie closes $10.9B Apogee deal to expand immunology pipeline
Sep 03 2026, 13:01
Ivonescimab beats Keytruda on survival in 4th phase 3 win
Sep 02 2026, 22:28
Moderna stock doubles in August after melanoma trial win with Merck
Sep 01 2026, 11:27
Lilly Taltz-Zepbound combo sustains 30.6% skin-clearance goal at 52 weeks
Aug 31 2026, 14:34
Eli Lilly to buy Merida Biosciences for up to $2.875 billion
Aug 31 2026, 14:14
Amgen's Repatha cuts death risk 20% in high-risk primary prevention trial
Aug 31 2026, 12:24
Moderna stock surges 127% as cancer vaccine reshapes biotech outlook
Aug 30 2026, 17:52
Eli Lilly GLP-1 sales surge 48% as employer coverage falls to 60%
Aug 28 2026, 20:22
FDA approves Lilly's Mounjaro to cut cardiovascular risk 8%
Aug 28 2026, 12:35
Gilead's Bixlenvo wins FDA approval as first single-tablet HIV option
Aug 27 2026, 22:26
Pfizer, BioNTech win FDA approval for XFG COVID vaccine, 5B doses
Aug 27 2026, 20:54
FDA clears Roche, Eli Lilly Alzheimer's blood test for 55-plus patients
Aug 27 2026, 15:55
Tezspire meets EoE trial goals, expanding to 470,000 US patient pool
Aug 27 2026, 10:27